# US 2023/0330030 A1 · Biodegradable polymer formulations for extended efficacy of botulinum toxin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0330030 A1
- Document ID: US20230330030A1
- Status: Published application
- Kind: A1
- Application number: 18/337,341
- Filed: 2023-06-19
- Published: 2023-10-19
- Earliest claimed: 2016-08-26
- Assignees: SK Joint Ventures II, LLC
- Applicants: SK Joint Ventures II, LLC
- Inventors: Kinam Park; Yeonhee Yun; Sarah Michelle Skidmore; Byung Kook Lee; John Solomon Garner
- Web page: https://patentgrep.com/patent/US20230330030A1

## CPC

- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/143: {with inorganic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- C01G 9/04: Halides
- C08G 63/08: Lactones or lactides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/113: Multiple emulsions, e.g. oil-in-water-in-oil {(A61K9/0026 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C01G: COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts or peroxyacids C01B15/00; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium, or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds containing nitrogen, other non-metals and metal C01B21/082}; metal amides C01B21/092; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanamide C01C3/16; thiocyanates C01C3/20)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

Methods for the formulation of biodegradable microparticles for delivery of protein drugs, such as botulinum toxin, have been developed. The methods include the steps of precipitating and washing proteins with organic solvent to remove water prior to dispersing in polymer-dissolved organic solvent to prevent exposure to water/solvent interfaces and maintain bioactivity of the protein drugs and fabrication of microparticles by either template or emulsion method. Biodegradable microparticles, formed of one or more biodegradable polymers having entrapped in the polymer one or more protein agents, such as botulinum toxin, are also provided. Precipitated botulinum toxin and botulinum toxin-loaded microparticles can also be formulated into thermogels or crosslinked hydrogels. The stability of the protein within these microparticles, as well as the controlled release of the entrapped agents, provides for sustained efficacy of the agents.

## Claims

### Claim at position 1

1-49. (canceled)

### Claim 50

A method of reducing or preventing one or more symptoms of a diseases, disorder or cosmetic defects in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of polymer particles having uniformly dispersed therein between about 100 units and about 50,000 units of botulinum toxin complexed with a protein bulking agent and precipitated by a precipitating agent selected from the group consisting of L-histidine methyl ester, L-cysteine ethyl ester, Na-(tert-butoxycarbonyl)-L-asparagine, L-proline benzyl ester, N-acetyl-L-tryptophan, gentisic acid, pentetic acid, octanoic acid, zinc chloride, and combinations thereof,
wherein the precipitated botulinum toxin complexed with the protein bulking agent is washed with a wash solvent prior to encapsulation, wherein the wash solvent retains the toxicity of the botulinum toxin in a mouse lethality test at 48 hours at a dose of 10 units/injection and is selected from the group consisting of acetone, acetonitrile, dioxane, ethanol, 2-methoxy ethyl acetate, methoxy ethanol, ethoxy ethanol, butoxy ethanol, 2-propanol, propylene glycol methyl ether, ethanediol, 1,2-propanediol, tert-butyl alcohol, diethylene glycol, and combinations thereof, wherein the botulinum toxin is released in an effective amount over a period of weeks.

### Claim 51 (depends on 50)

The method of claim 50, wherein one or more diseases, disorders or cosmetic defects to be treated is selected from the group consisting of hemorrhagic cystitis, interstitial cystitis/painful bladder syndrome, hemorrhagic cystitis, IC/PBS, hematuria, urinary urgency, supra pubic pain, inflammation, and urinary retention, crossed eyes (strabismus), uncontrolled blinking (blepharospasm), muscle stiffness/spasms, cervical dystonia, torticollis, uncontrollable sweating, undesirable wrinkles, headaches and migraines.

### Claim 52 (depends on 50)

The method of claim 50, wherein the polymer particles are dispersed in a diluent consisting of an aqueous thermosensitive polymer solution.

### Claim 53 (depends on 52)

The method of claim 52 wherein the aqueous thermosensitive polymer solution transitions between liquid and gel within the range of 4° C. to 40° C.

### Claim 54 (depends on 52)

The method of claim 52 wherein the aqueous thermosensitive polymer solution transitions between liquid and gel within the range of 20° C. to 38° C.

### Claim 55 (depends on 52)

The method of claim 52 wherein the aqueous thermosensitive polymer is selected from poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide), poly(lactide)-b-poly(ethylene glycol)-b-poly(lactide), poly(lactide-co-caprolactone)-b-poly(ethylene glycol)-b-poly(lactide-co-caprolactone), poly(caprolactone)-b-poly(ethylene glycol)-b-poly(caprolactone), methoxy poly(ethylene glycol)-b-poly(caprolactone), or combinations thereof.

### Claim 56 (depends on 52)

The method of claim 52 wherein the aqueous thermosensitive polymer solution contains the thermosensitive polymer at a concentration between 5% and 40% (w/v).

### Claim 57 (depends on 50)

The method of claim 50, wherein the polymer particles are dispersed in a diluent consisting of a gel-forming solution or a gel.

### Claim 58 (depends on 57)

The method of claim 57 wherein the gel-forming solution is hyaluronic acid and the gel is crosslinked hyaluronic acid.

### Claim 59 (depends on 50)

The method of claim 50, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G, and mixtures thereof.

### Claim 60 (depends on 50)

The method of claim 50 further comprising one or more therapeutic, prophylactic, or diagnostic agents.

### Claim 61 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual for treatment of uncontrollable sweating.

### Claim 62 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual to enhance the cosmetic appearance of wrinkles.

### Claim 63 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual to prevent headaches in people with very frequent migraines,

### Claim 64 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual by intramuscular injection into the affected muscles when treating eye disorders or muscle stiffness/spasms.

### Claim 65 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual by injection into wrinkles in the skin.

### Claim 66 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual for treatment of bladder disorders including hemorrhagic cystitis, interstitial cystitis/painful bladder syndrome (IC/PBS), and cancer.

### Claim 67 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual in an amount effective to alleviate pain, inflammation, or urinary urgency.

### Claim 68 (depends on 67)

The method of claim 67 wherein the particles are administered to an individual by injection into the muscles or lumen of the bladder.

### Claim 69 (depends on 67)

The method of claim 67 wherein the particles are administered to an individual by instillation into the bladder.

### Claim 70 (depends on 51)

The method of claim 51 wherein the particles are administered to an individual to treat crossed eyes (strabismus) or uncontrolled blinking (blepharospasm).
